PENNANT GROUP INC PNTG 深 滬
已收盤 08-01 16:00:00 美东时间
22.07
-0.100
-0.45%
華盛通- 最 高22.285
- 今 開22.00
- 成交量 35.68万股
- 最 低 21.73
- 昨 收 22.17
- 總市值 7.61亿
- 52周最高 37.13
- 市盈率 靜 31.30
- 換手率 1.04%
- 52周最低 21.18
- 委 比 -99.32%
- 總股本 3446.90万
- 歷史最高 69.56
- 量 比 1.38
- 振 幅 2.50%
- 歷史最低 6.15
- 每 手 1
- 風險率 3.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pennant Announces Second Quarter 2025 Earnings Release and Call
The Pennant Group, Inc. announced it will release its second quarter 2025 financial results on August 6, 2025, and host a live webcast on August 7, 2025, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time). Investors can access the webcast or related financial information at http://investor.pennantgroup.com, which will be available for replay until August 6, 2026. The company provides home health, hospice, and senior living services through its...
07-22 23:05
Breaking Down Pennant Gr: 4 Analysts Share Their Views
Pennant Gr (NASDAQ:PNTG) has been analyzed by 4 analysts in the last three mont...
07-17 02:00
Truist Securities Maintains Hold on Pennant Gr, Lowers Price Target to $28
Truist Securities analyst David Macdonald maintains Pennant Gr (NASDAQ:PNTG) with a Hold and lowers the price target from $32 to $28.
07-16 22:27
Proposed Medicare payment cut for home health could scuttle UnitedHealth/Amedisys deal
A Raymond James analyst is warning that a just proposed 6.4% cut in Medicare payments to home health care agencies in 2026 introduced by the Trump administration could be a "death knell" for UnitedHea...
07-01 23:17
Pennant Announces Home Health Acquisition in Southern California
The Pennant Group has acquired GrandCare Health Services, renaming it GrandCare Home Health. The purchase expands Pennant's home health services in Southern California, including Los Angeles, Orange, Riverside, and San Diego counties. Pennant CEO Brent Guerisoli emphasized the strategic importance of this move, as it enhances their presence in a region where they already have a strong senior living network. GrandCare is known for its high-quality...
07-01 20:44
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Stephens & Co. Reiterates Overweight on Pennant Gr, Maintains $35 Price Target
Stephens & Co. analyst Raj Kumar reiterates Pennant Gr (NASDAQ:PNTG) with a Overweight and maintains $35 price target.
06-10 22:13
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
Wells Fargo Maintains Equal-Weight on Pennant Gr, Raises Price Target to $31
Wells Fargo analyst Stephen Baxter maintains Pennant Gr (NASDAQ:PNTG) with a Equal-Weight and raises the price target from $30 to $31.
06-03 20:45
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
